Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
June 23, 2016updated 02 Dec 2021 9:25am

Report: Licensing deal values in the pharmaceutical industry surged in 2015, led by Sanofi

The value of licensing deals in the pharmaceutical industry reached $46.2bn last year, recording a signigicant growth of 37.1% over last year’s $33.7bn, says a whitepaper by GlobalData.

The value of licensing deals in the pharmaceutical industry reached $46.2bn last year, recording a signigicant growth of 37.1% over last year’s $33.7bn, says a whitepaper by GlobalData. The surge in the licensing deal values is attributed primarily to Sanofi’s three sizeable deals worth approximately $9bn.

The whitepaper titled ‘Pharmaceutical Sector Brief – Pharma Licensing Values Soar to New Levels‘, details the deals signed by Sanofi that led to the record values of the licensing deal market. The pharmaceutical company signed a $4.3bn deal with South Korea’s Hanmi Pharma and acquired an exclusive global license to develop and market three type 2 diabetes treatment products in the pipeline. Another deal worth $1.7bn was signed with Lexicon Pharma for sotagliflozin (LX-4211).

“We believe deal prices will continue to rise in 2016.”

Analysing the licensing deals, the GlobalData whitepaper states that the immune-oncology (I-O) space is also witnessing a rise in investment on deals. Sanofi’s third significant deal, valued at $2.7bn, was signed in the I-O market, in order to co-develop Regeneron’s REGN-2810.

Another key deal in the I-O market was the agreement between Pfizer and Merck KGaA to develop and market avelumab (MSB-0010718C). The deal for the potential treatment for multiple metastatic and advanced solid tumours is worth $2.9bn. The treatment is currently in its Phase II of development. Merck KGaA will receive $850m as upfront payment in connection with the deal.

GlobalData’s deals analyst Gianfranco Zeppetelli explains: “Pharma companies are adapting to current market dynamics and positioning themselves for growth through portfolio transformation, targeted deal-making, cost-cutting measures and sharpening their focus on high-performing therapeutic areas and geographic markets.”

“We believe deal prices will continue to rise in 2016, as many big pharma companies look to increase their market share in specific therapeutic areas against their competitors.”

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU